Cardionyx is a pre-seed stage company developing an active implant to stimulate baroreceptors for Heart Failure (HF) patients, through a minimally invasive approach.

Cardionyx stands at the forefront of medical innovation, poised to address the critical clinical needs of Heart Failure (HF) patients with reduced ejection fraction (HFrEF) through its groundbreaking approach.

With a relentless focus on improving the lives of patients facing diminished life expectancy, frequent hospitalizations, and compromised quality of life (QOL), Cardionyx is developing a first-of-its-kind trans-vessel active implant designed to stimulate electricly baroreceptors, offering a potential game-changer in HF treatment.

Unlike conventional therapies, which often leave a significant portion of patients ineligible or poorly managed, Cardionyx redefines the possibilities of intervention.

At the core of this innovation lies an implant that leverages venous catheterization for implantation, ensuring a safer and quicker procedure which fits the clinical profile of this patient population.

Another aspect that truly sets Cardionyx apart is its ability to provide personalized therapy coupled with real-time hemodynamic monitoring, allowing for the dynamic regulation of parasympathetic tone.

This unique feature enables adjustable upregulation according to the patient's evolving hemodynamics, maximizing efficacy while minimizing adverse events and reducing the likelihood of baroreceptor desensitization.

With preclinical proof validating its approach and a substantial market opportunity estimated at $1.4 billion for severe to moderate patients (NYHA III-IV) and an additional $2.2 billion for mild patients (NYHA II), Cardionyx is well-positioned to make a significant impact.

Having already secured $700,000 in funding through a SAFE in August 2023, the company is now seeking to raise $1.3 million in pre-seed funding to fuel its continued growth and development.